Comparison of Treatment Modalities in Poor Responders Undergoing IVF

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02158689

Enrollment

Registered

2014-06-09

Start date

2014-06-30

Completion date

2015-08-31

Last updated

2016-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poor Responders

Keywords

Poor responders, letrozole, human menopausal gonadotropin

Brief summary

The accurate identification and efficient management of poor responders remains one of the most enigmatic challenges in assisted reproductive technology (ART). The investigators study will compare the letrozole/antagonist protocol to the hMG/antagonist protocol in women who poor responders.

Interventions

DRUGLetrozole

DRUGhuman menopausal gonadotropin (hMG)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 42 Years

Healthy volunteers

Inclusion criteria

* Patients will be considered eligible if they are poor ovarian responders according to the Bologna criteria (Ferraretti et al., 2011). * Two out of three of the following criteria are essential in order to classify a patient as poor ovarian responder: * advanced maternal age (≥40 years) or any other risk factor for poor ovarian response; * a poor ovarian response (≤3 oocytes with a conventional stimulation protocol); or * an abnormal ovarian reserve test (antral follicle count, \<7 follicles or anti-Mullerian hormone, \<1.1 ng/ml).

Design outcomes

Primary

Measure	Time frame	Description
Ongoing pregnancy rate	up to 2 weeks	The primary outcome measure will be the ongoing pregnancy rate (\>12 weeks' gestation) per started cycle.

Secondary

Measure	Time frame	Description
Cancellation Rate	up to one month	One of the secondary outcome measures will be cancellation rate.
Number of oocytes retrieved	up to one month	One of the secondary outcome measures will be number of oocytes retrieved.
Number of transferable embryos	up to one month	One of the secondary outcome measures will be number of transferable embryos.
Implantation rate	up to 2 weeks	One of the secondary outcome measures will be implantation rates.
Clinical pregnancy rate	up to 2 weeks	One of the secondary outcome measures will be clinical pregnancy rates.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026